Cemivameran

Approval Year

Substance Class	Nucleic Acid Created by `admin` on `Wed Apr 02 19:51:09 GMT 2025` Edited by `admin` on `Wed Apr 02 19:51:09 GMT 2025`
Nucleic Acid Type	mRNA VACCINE
Sequence Origin	VIRAL
Sequence Type	COMPLETE
Record UNII	3W7YFK5FNA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Cemivameran

Official Name

English

BNT162b2 Omicron (KP.2)

Preferred Name

English

messenger RNA (mRNA), 5'-capped, encoding a fulllength, codon-optimised pre-fusion stabilised conformation variant (K982P and V983P) of the SARSCoV-2 (severe acute respiratory syndrome coronavirus 2) spike (S) glycoprotein (Omicron KP.2 variant; GISAID:

Common Name

English

cemivameran [INN]

Common Name

English

RNA (recombinant 5?-[1,2-[(3?-O-methyl)m7G-(5??5?)-ppp-Am]]-capped all uridine?N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptide plus codon-optimized pre-fusion spike glycoprote

Common Name

English

Code System Code Type Description

INN

13743

Created by admin on Wed Apr 02 19:51:09 GMT 2025 , Edited by admin on Wed Apr 02 19:51:09 GMT 2025

PRIMARY

CAS

3036385-75-5

Created by admin on Wed Apr 02 19:51:09 GMT 2025 , Edited by admin on Wed Apr 02 19:51:09 GMT 2025

PRIMARY

FDA UNII

3W7YFK5FNA

Created by admin on Wed Apr 02 19:51:09 GMT 2025 , Edited by admin on Wed Apr 02 19:51:09 GMT 2025

PRIMARY

Sugar	Site Range	Site Count
D-Ribose (RNA)	1_1-1_4271	4271 / 4271

Linkage	Site Range	Site Count
Phosphate	1_2-1_4271	4270 / 4270

Related Record Type Details


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->VACCINE ANTIGEN

Amount:


					N36VHK46PR

Raxtozinameran

PARENT->MUTANT

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
BASE REPLACEMENT (NON-CODING)	[1_1]	5'-TERMINUS			m2-7,3’-OGppp(m1-2’-O)Ap mRNA CAP	VNP8CZY34V
NUCLEOSIDE_SUBSTITUTION			U		N1-METHYLPSEUDOURIDINE	09RAD4M6WF